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Neisseria gonorrhoeae has developed resistance to multiple classes of antimicrobials. There is now growing
concern that without the availability of appropriate public health strategies to combat this problem, gonorrhea
could become untreatable. For this reason, surveillance for gonococcal antimicrobial resistance must be
optimal both in terms of obtaining a representative sample of gonococcal isolates and in terms of having the
appropriate tools to identify resistance. To aid with this surveillance, molecular tools are increasingly being
used. In the present study, we investigated the use of a simple heat denaturation protocol for isolate DNA
preparation combined with SYBR green-based real-time PCR for the identification of mutations associated
with N. gonorrhoeae antimicrobial resistance. A total of 109 clinical gonococcal isolates were tested by high-
resolution melting (HRM) curve analysis for chromosomal mutations associated with gonococcal resistance to
beta-lactam antibiotics: a penA 345A insertion, ponA L421P, mtrR G45D, substitutions at positions 120 and 121
in porB1b, and an adenine deletion in the mtrR promoter. An allele-specific PCR assay was also investigated
for its ability to detect the adenine deletion in the mtrR promoter. The results were compared to those obtained
by DNA sequencing. Our HRM assays provided the accurate discrimination of heat-treated isolates in which
the sequence types differed in GC content, including isolates with the penA 345A insertion and the ponA L421P
and mtrR G45D mutations. The allele-specific PCR assay accurately identified isolates with the adenine
deletion in the mtrR promoter. Heat-denatured DNA combined with SYBR green-based real-time PCR offers a
simple, rapid, and inexpensive means of detecting gonococcal resistance mechanisms. These methods may have
broader application in the detection of polymorphisms associated with phenotypes of interest.
Neisseria gonorrhoeae is the etiologic agent of the sexually
transmitted disease gonorrhea, causing an estimated 60 million
new infections annually (7). In females, gonorrhea is a major
cause of pelvic inflammatory disease and may lead to tubal
infertility, ectopic pregnancy, and chronic pelvic pain, whereas
in males it primarily causes urethritis (2, 3, 7). The control of
gonorrhea is achieved through the provision of effective anti-
microbial therapy to eradicate the infection, reduce transmis-
sion, and prevent the development of complications. However,
N. gonorrhoeae has managed to develop resistance to multiple
classes of antimicrobials, including penicillins and tetracy-
clines, and quinolones have been withdrawn from use in many
parts of the world because of widespread resistance. Even the
more recently available macrolides now have limited utility,
leaving extended-spectrum cephalosporins (both oral and in-
jectable) and spectinomycin (when it is available) as the main-
stays of treatment. Without appropriate public health strate-
gies to combat this problem, there is a real threat that
gonorrhea will become untreatable (18). The Centers for Dis-
ease Control and Prevention has recently expressed fears re-
garding the ability to control gonorrhea, the need to explore
alternate treatment options as a response to the increasing
cephalosporin resistance in N. gonorrhoeae, and the require-
ment for enhanced monitoring of gonococcal resistance glo-
bally (4, 30).
The volatile nature of antimicrobial resistance in gonococci
means that surveillance for resistance for public health pur-
poses must be optimal both in terms of obtaining a sufficiently
large and representative sample of gonococcal isolates and in
terms of using the appropriate tools to identify resistance (19).
The increasing use of nucleic acid amplification assays in in-
dustrialized countries and the widespread application of syn-
dromic management principles in less developed countries
have increasingly restricted the availability of gonococcal iso-
lates for the phenotypic detection of resistance rates. Logistical
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problems with gonococcal storage and transport and the in-
trinsic fragility of N. gonorrhoeae also have adverse effects on
the availability of viable isolate (21, 31).
Molecular tools are being used to provide an understanding
of the genetic basis of resistance as well as to supplement
phenotypic antimicrobial susceptibility testing (9, 15, 16, 20, 22,
23, 24). These tools have not yet advanced to a stage where
they can be used in place of phenotypic testing, mainly because
the genetic determinants of resistance to most antibiotics are
not yet fully known. Nevertheless, for well-characterized resis-
tance mechanisms, molecular tools offer an accurate and ob-
jective means of detection and systems for the detection of
pivotal resistance determinants for public health purposes
when viable isolates are not required have been described
(22, 23).
An ongoing limitation of molecular assays is that they can be
prohibitively expensive. The advent of real-time PCR technol-
ogy has, for the most part, alleviated the need for costly DNA
sequencing. However, real-time PCR assays targeting gono-
coccal resistance mechanisms have to date predominantly
combined initial DNA extraction with probe-based real-time
PCR. Both of these factors can impinge on the cost-effective-
ness of the use of real-time PCR; commercial DNA extraction
methods can be expensive, and the use of fluorophore-labeled
probes can involve considerable initial setup costs. This is par-
ticularly the case when multiple mutations are being investi-
gated, as different probe sets specific for each mutation need to
be purchased. Furthermore, we have found that the accuracy
of probe-based real-time PCR can be undermined by unex-
pected variations in the sequences of the probe targets (28, 29).
This is particularly relevant to N. gonorrhoeae, given that the
species comprises numerous subtypes that exhibit considerable
sequence diversity (25, 27) as well as because some of the
genes implicated in conferring resistance, including porB1b,
are highly variable.
In the study described here, we sought to develop a simple
and cost-effective means of identifying mutations associated
with gonococcal resistance for potential applications in screen-
ing for antimicrobial resistance for public health purposes. We
did this using two approaches: first, we sought to use a simple
heat denaturation protocol rather than DNA extraction for
isolate DNA preparation to decrease costs and the preparation
time. This also allows the examination of nonviable organisms.
Second, we used SYBR green-based real-time PCR, thereby
removing the need for the initial purchase of expensive fluoro-
phore-labeled probes and allowing the use of only a single
primer pair. Briefly, the study was conducted by developing
high-resolution melting (HRM) curve analysis assays targeting
five key chromosomal mutations associated with gonococcal
resistance to beta-lactam antibiotics, including an Asp-345A
codon insertion in the penA gene, which encodes penicillin
binding protein 2 (PBP 2) (5, 6); the L421P substitution in the
ponA gene, which encodes PBP 1 (13); a G45D substitution in
the encoding region of the mtrR gene (32); an adenine deletion
in the mtrR promoter region (32); and various substitutions in
amino acids 120 and 121 of the porB1b protein (8, 12). An
allele-specific PCR assay was also investigated for its ability to
detect the adenine deletion in the mtrR promoter.
MATERIALS AND METHODS
N. gonorrhoeae strains and heat denaturation. A total of 109 gonococcal
clinical isolates were selected and tested using the real-time PCR assays. These
isolates were selected on the basis of their geographical and temporal diversity
and ceftriaxone MIC and formed part of the isolates used in a previous study
(26). Briefly, the isolates included local and international strains and comprised
13 isolates from various parts of Asia, with the remaining 96 strains coming from
various regions of the Australian state of New South Wales. The years of
isolation were 1988 (n  3), 1997 (n  1), 1999 (n  1), 2000 (n  3), 2001 (n 
12), 2002 (n  11), 2003 (n  7), 2004 (n  12), and 2005 (n  59). Heat
denaturation was performed by selecting three to six colonies from a 24-h
single-colony subculture of each isolate, suspending the colonies in 1.0 ml of
distilled water in a 1.5-ml tube, and heating the tubes at 100°C for 8 min.
Primer design. For the HRM curve analysis-based real-time PCR assays,
primers were designed to flank the sequences or the codons of interest. For PCR
assays targeting the penA 345A insertion and the ponA1 L421P and mtrR G45D
substitutions, the forward and reverse primers directly flanked a single codon
TABLE 1. Oligonucleotides used in this study
Assay and primer name Sequence Target Positiona Product size (bp)
HRM curve analysis
penA-345A-F CGTCTCCCGTGCGCGA penA 1516143–1516128 38 (wild type), 41 (345A insertion)
penA-345A-R CAAAGAGGGGTAAACATGGGTA penA 1516103–1516124
ponA1-L421P-F GTGGTTCAAGAGCCGTTG ponA 109910–109927 38
ponA1-L421P-R GAAACCAAAGCCCCCTG ponA 109947–109931
mtrR-G45D-F CCGGCGTAACGCGC mtrR 1327916–1327929 39
mtrR-G45D-R TTTTGAAATGCCAATAGAGCGC mtrR 1327954–1327933
porB-120-F CAGCCCCCTGAAAAACACC porB 1789036–1789054 46
porB-121-R GGATTCCCAAGCATTGACGTT porB 1789081–1789061
mtrRprom-F TATACATACACGATTGCACGGA mtrR promoter 1327718–1327739 49 (wild type), 48 (A deletion)
mtrRprom-R AGGGCGGATTATAAAAAAGAC mtrR promoter 1327766–1327746
Allele-specific PCR
mtrRprom-ASP-F1 CATACACGATTGCACGGATAAAA mtrR promoter 1327722–1327744 65 (wild type), 64 (A deletion)
mtrRprom-ASP-F2 TACACGATTGCACGGATAAAAAG mtrR promoter 1327724–1327746 63 (wild type), 62 (A deletion)
mtrRprom-ASP-R CGTTTCGGGTCGGTTTGA mtrR promoter 1327786–1327769
a Positions in the complete genome of N. gonorrhoeae FA1090 (GenBank accession number AE004969).
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(primers penA-345A-F and penA-345A-R, ponA1-L421P-F and ponA1-L421P-R,
and mtrR-G45D-F and mtrR-G45D-R, respectively; Table 1). For the detection
of substitutions at positions 120 and 121 of the porB1b protein, a single primer
pair (primers porB-120-F and porB-121-R) was used to directly flank both codons
(Table 1). For the mtrR promoter assay, primers were designed to flank the
region with the adenine deletion (primers mtrRprom-F and mtrRprom-R; Table
1). The PCR product sizes for these assays ranged from 38 to 49 bp (Table 1).
The assays were designed so that different sequence types could be distinguished
by HRM curve analysis.
An allele-specific primer (ASP)-based method was also designed to detect the
adenine deletion in the mtrR promoter. This method used two real-time PCRs
for each isolate. The first reaction (the ASP-based control PCR [ASP-control-
PCR]) used forward primer mtrRprom-ASP-F1 and reverse primer mtrRprom-
ASP-R (Table 1), which were designed to have a 100% match with the mtrR
promoter sequences of both wild-type gonococcal strains and gonococcal strains
with the adenine deletion (Fig. 1). The ASP-controlPCR therefore served as the
amplification control. The second reaction (the ASP-based PCR for the detec-
tion of the adenine deletion [ASP-A-deletPCR]) used the same reverse primer as
the ASP-controlPCR but used forward primer mtrRprom-ASP-F2. Compared to
the sequence of primer mtrRprom-ASP-F1, the sequence of primer mtrRprom-
ASP-F2 was moved up the target sequence by 2 bases, placing the primer target
across the region with the adenine deletion. Primer mtrRprom-ASP-F2 therefore
matches 100% with the sequence of wild-type gonococci, but the 2 bases on the
extreme 3 end mismatch the sequence of gonococci with the adenine deletion
(Fig. 1). This mismatch resulted in an identifiable delay in the ASP-A-deletPCR
cycle threshold (CT) value compared to the ASP-controlPCR CT value for iso-
lates with the adenine deletion.
Reaction mixture and cycling conditions. All HRM assays and allele-specific
real-time PCRs were performed with a standard reaction mixture and standard
cycling conditions. Each reaction mixture contained 10.0 l of 2 SYBR green
quantitative PCR SuperMix-UDG (Invitrogen, Australia), 0.5 M of forward
and reverse primers, and 2.0 l of heat-denatured isolate and was made up to a
total volume of 20.0 l with DNase-free water. Cycling was performed on a
RotorGene 6000 instrument (Corbett Life Science, Australia) with the following
two-step cycling conditions: an initial enzyme activation step at 95°C for 2 min,
followed by 40 cycles of denaturation at 95°C for 10 s and primer annealing and
elongation at 60°C for 30 s, with the fluorescence signal being read on green at
60°C following extension. HRM curve analysis was performed following PCR
amplification; the reaction mixtures were continuously analyzed from 60°C to
95°C with temperature increments of 0.5°C/s.
Control specimens. Appropriate heat-denatured isolate controls of known
sequence types, as determined by DNA sequencing, were included for all test
runs. For the assay for the detection of substitutions at positions 120 and 121 in
porB1b, eight isolate controls of different sequence types were used: GS (codons
GGCAGC), DA (GACGCC), KG (AAGGGC), KD (AAGGAC), KN (AAGA
AC), NA (AACGCC), and two different GA sequence types (GA1 and GA2;
codons GGTGCC and GGCGCC, respectively).
For the remaining assays there were two sequence controls for each test run.
These included the penA wild type and the penA 345A insertion (codon CGA),
ponA L421 (CTG) and ponA1 421P (CCG), mtrR G45 (GGC) and mtrR 45D
(GAC), and the mtrRpromoter wild type and the mtrRpromoter adenine dele-
tion. Two negative (no-DNA) controls were also included in each test run.
Real-time PCR result interpretation. Analysis of the HRM assay results was
performed with RotorGene 6000 HRM software (Corbett Life Science) with a
confidence setting of 90%. In each run, the results for the test isolates were
compared to those for the respective controls.
For the mtrR promoter allele-specific PCR, the results were determined on the
basis of the CT values. Briefly, the difference in CT values observed in the
ASP-A-deletPCR and ASP-controlPCR assays was determined for each isolate.
This delta CT value was then used to assign the sequence type.
DNA sequencing. The results of the HRM and allele-specific real-time PCR
assays were compared to the results of DNA sequencing of the penA, ponA, mtrR,
porB, and mtrR promoter sequences for all 109 isolates. Briefly, previously
described primers were used to amplify the ponA (GAAAATGGGGGAGGAC
CGTA and TTAAAACAGGGAATCCAACTGC [13, 14]) and mtrR (AACAG
GCATTCTTATTTCAG and TTAGAAGAATGCTTTGTGTC [11]) sequences
by PCR. The PCR products were sent to the Australian Genome Research
Facility (http://www.agrf.org.au/) for automated fluorescent sequencing. The
penA and porB sequences for all isolates were available from a previous study
(26).
RESULTS
HRM curve analysis. The results for the HRM real-time
PCR assays compared to those of DNA sequencing for 109
isolates are summarized in Table 2. The results of HRM assay
detection of the wild-type ponA and mutated ponA1 sequences
provided 100% agreement with the results of DNA sequencing
for all 109 isolates. For mtrR codon 45, the HRM assay cor-
rectly identified 22 isolates with the G45D mutation and 86
isolates with the wild-type sequence. However, one isolate with
a G45S sequence (codon AGC) was incorrectly assigned a
G45D sequence type (GAC) by the HRM assay. For the mtrR
promoter sequence, the results of the HRM assay and DNA
sequencing were in agreement for 103 of the 109 isolates: 77
isolates with the A deletion and 26 isolates with the wild-type
sequence. However, four isolates with the A deletion were
incorrectly assigned to the wild type by the HRM method, and
one isolate with the wild-type sequence was incorrectly as-
signed as having an A deletion. One isolate with an A deletion
could not be assigned a sequence type by the mtrR promoter
HRM assay.
The penA HRM assay correctly identified all 95 isolates
displaying the 345A codon insertion; however, it failed to as-
sign a sequence type for 11 of 14 wild-type isolates. These 11
isolates were not assigned a sequence type by the HRM anal-
ysis software because their sequences failed to be amplified by
the penA assay. DNA sequencing showed that all 11 isolates
possessed the previously described mosaic penA sequence (1,
26). The failure to be amplified was due to primer mismatches
with the mosaic penA sequence (Table 3). For analysis of the
porB1b codons at positions 120 and 121, HRM analysis cor-
rectly identified isolates with sequence types GA2, KD, KG,
KN, and NA but could not readily distinguish sequence types
DA, GA1, and GS. An additional five isolates were not as-
signed a sequence type by the porB1b HRM assay. These
isolates possessed porB1a (and not porB1b) genes and could
FIG. 1. Primer design for the mtrR promoter allele-specific PCR. The sequences of all primers except primer mtrRprom-ASP-F2 matched 100%
both the wild-type sequence and the sequence with the adenine deletion; primer mtrRprom-ASP-F2 had two mismatches at the 3 end (circled)
compared to the sequence with the adenine deletion.
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not be amplified in the assay because of primer mismatches
(data not shown). The results of DNA sequencing also showed
that numerous other sequence mismatches were present in the
primer targets of the HRM assays but that these mismatches
did not have an effect on the sequence type results assigned by
HRM curve analysis (Table 3).
Allele-specific PCR. By the allele-specific PCR, the 27 iso-
lates with the wild-type mtrR promoter sequence were readily
distinguished from the 82 isolates with the A deletion on the
basis of the delta CT values from the ASP-controlPCR and the
ASP-A-deletPCR; isolates with the wild-type sequence (as de-
termined by DNA sequencing) provided delta CT values rang-
TABLE 2. Summary of HRM real-time PCR and DNA sequencing results
Sequence No. isolates(n  109)
Sequence type by: HRM confidence (%) Melting temp (°C)
No. of GC bases
(% GC content)DNA sequencing HRM real-timePCR Range
Mean,
median Range
Mean,
median
ponA 94 L421P (CCG) L421P (CCG) 93.5–100 98.9, 99.6 79.25–79.85 79.58, 79.5 23 (60.5)
15 Wild type (CTG) Wild type (CTG) 98.1–100 99.8, 99.9 78.5–78.9 78.64, 78.65 22 (57.9)
penA 95 345A (CGA) 345A (CGA) 94.8–99.7 98.9, 99.4 77.75–78.1 77.95, 77.9 24 (58.5)
3 Wild type Wild type 99.1–99.6 99.5, 99.6 76.6 76.6, 76.6 22 (57.9)
11a Mosaica Varianta,b No confidence
dataa
No confidence
dataa
No melting
curvea
No melting
curvea
mtrR 22 G45D (GAC) G45D (GAC) 98.4–100 99.6, 99.8 77.4–77.6 77.5, 77.5 22 (56.4)
1 G45S (AGC) G45D (GAC) 100 77.5 22 (56.4)
86 Wild type (GGC) Wild type (GGC) 94.8–100 99.5, 99.8 78.65–79 78.79, 78.75 23 (59.0)
mtrR promoter 77 A deletion A deletion 96.5–100 99.1, 99.4 70.75–70.9 70.76, 70.75 17 (35.4)
1 A deletion Variant No confidence
data
No confidence
data
70.5 17 (35.4)
4 A deletion Wild type 94.1–98.5 97.2, 98.1 70.5–70.75 70.65, 70.75 17 (35.4)
26 Wild type Wild type 94.1–100 98.7, 98.9 70.5–70.75 70.62, 70.6 17 (34.7)
1 Wild type A deletion 97.3 70.75 17 (34.7)
porB 3 DA (GACGCC) DA (GACGCC) 98.9–99.7 99.3, 99.2 78.12–78.37 78.27, 78.3 26 (56.5)
(amino acids
120 and 121)
4 DA (GACGCC) GA1 (GGTGCC) 91.4–99.9 97.7, 99.6 78.1–78.3 78.23, 78.22 26 (56.5)
5 GA1 (GGTGCC) GA1 (GGTGCC) 99–99.9 99.5, 99.4 78.1–78.25 78.2, 78.22 26 (56.5)
4 GA2 (GGCGCC) GA2 (GGCGCC) 95.2–99.8 98.4, 98.9 79.18–79.38 79.28, 79.25 27 (58.7)
2 GS (GGCAGC) DA (GACGCC) 99.2–99.6 99.4, 99.2 78.35–78.37 78.36, 78.35 26 (56.5)
4 GS (GGCAGC) GS (GGCAGC) 98.5–99.8 99.2, 99.2 78.32–78.53 78.38, 78.33 26 (56.5)
75 KD (AAGGAC) KD (AAGGAC) 90.2–99.9 97.3, 97.7 75.77–76.42 76.18, 76.2 24 (52.2)
1 KG (AAGGGC) KG (AAGGGC) 99.0 77.15 25 (54.3)
2 KN (AAGAAC) KN (AAGAAC) 99.1–99.3 99.2, 99.1 75.3–75.4 75.35, 75.3 23 (50.0)
4 NA (AACGCC) NA (AACGCC) 98.1–99.1 98.4, 98.1 77.45–77.52 77.49, 77.5 25 (54.3)
5 porB1a Variantc No confidence
datac
No confidence
datac
No melting
curvec
No melting
curvec
a These isolates contained the mosaic penA sequence, and their sequences were not amplified in the penA HRM assay due to mismatches in the primer targets.
b Variant, could not be assigned a sequence type by the HRM assay.
c These isolates contained a porB1a gene, and their sequences were not amplified in the porB1b HRM assay.
TABLE 3. Examples of sequence variations in primer targets and impact upon results of real-time PCR assays
No. of
isolates Assay Primer target(s) Sequence type Sequence
Impact on PCR
assay results
11 penA 345-A HRM assay Both primers Forward primer 5-CGTCTCCCGTGCGCGA-3 Varianta (failed to
amplify)Isolate penA 5-..G..A....A.AA..-3
Reverse primer 5-CAAAGAGGGGTAAACATGGGTA-3
Isolate penA 5-.....TA..A.....G......-3
3 mtrR G45D HRM assay Forward primer Primer 5-CCGGCGTAACGCGC-3 None
Isolate mtrR 5-............A.-3
9 mtrR G45D HRM assay Reverse primer Primer 5-TTTTGAAATGCCAATAGAGCGC-3 None
Isolate mtrR 5-................T.....-3
4 porB HRM assay Reverse primer Primer 5-GGATTCCCAAGCATTGACGTT-3 None
Isolate porB 5-..................T..-3
5 porB HRM assay Reverse primer Primer 5-GGATTCCCAAGCATTGACGTT-3 None
Isolate porB 5-.............CC......-3
1 mtrR promoter ASP assay Forward primer Primer 5-CATACACGATTGCACGGATAAAA-3 None
Isolate mtrR promoter 5-............G..........-3
1 mtrR promoter ASP assay Forward primer Primer 5-CATACACGATTGCACGGATAAAA-3 None
Isolate mtrR promoter 5-....A..................-3
a Variant, could not be assigned a sequence type by the HRM assay.
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ing from 0.1 to 2.5 cycles (mean, 0.6 cycles; median, 0.4 cycles),
whereas isolates with the A deletion provided delta CT values
ranging from 5.1 to 12.9 cycles (mean, 9.7 cycles; median, 9.8
cycles). Sequence variation was observed in the forward primer
for two isolates with the wild-type promoter sequence, but this
did not have an effect on the results of the allele-specific PCR
(Table 3).
DISCUSSION
Our results show that the penA 345A, ponA L421P, and mtrR
G45D HRM assays and the mtrR promoter allele-specific PCR
were accurate in distinguishing the sequence types of heat-
treated isolates. The results of the penA 345A and ponA L421P
HRM assays and the mtrR promoter allele-specific PCR were
in complete agreement with the results of DNA sequencing.
Only one incorrect mtrR G45D HRM curve analysis result was
observed.
These results show the HRM assays provide the accurate
discrimination of heat-treated isolates, so long as the sequence
types differ in their GC contents. The one isolate incorrectly
assigned to the G45D type by the mtrR HRM assay possessed
a rare AGC (G45S) codon (23) and therefore had the same
GC content and base composition as the G45D (GAC) se-
quence type. Likewise, the mtrR promoter HRM assay could
not readily distinguish the mtrR promoter sequence types,
which differed by only a single adenine deletion, and the porB
HRM assay had difficulty distinguishing the eight different
porB1b sequence types, some of which overlapped in GC con-
tents. To investigate the porB HRM analysis issue further, we
reanalyzed the porB HRM curve analysis data by excluding the
data for isolates and controls with genotypes GS, KG, and
GA1, such that the remaining five sequence types had different
GC contents: KN (AAGAAC), KD (AAGGAC), NA (AACG
CC), DA (GACGCC), and GA2 (GGCGCC). Upon reanaly-
sis, all five genotypes were accurately distinguished by the
HRM assay (data not shown). This confirms that the HRM
methods can readily distinguish multiple sequence types when
heat-denatured isolates are used, so long as the GC contents of
the sequence types are different. To further investigate the
mtrR promoter HRM assay, we performed several repeat test
runs and found that the incorrect sequence type assignment of
the assay was not restricted to particular isolates but in fact
occurred more randomly (data not shown). This further high-
lights the limited ability of the approach to accurately distin-
guish sequence types of similar GC content. Previous studies
have shown that the HRM assay is capable of distinguishing
different sequence types of the same GC content when purified
DNA is used at a defined concentration (10, 17). There is no
technical reason why the HRM assay could not be used to
accurately distinguish the eight sequence types associated with
the porB1b codons at positions 120 and 121 or the single
adenine deletion in the mtrR promoter investigated in this
study. However, the aim of this study was to find a simple and
cost-effective means of identifying mutations associated with
gonococcal resistance. The use of heat-denatured isolates
rather than purified DNA for this purpose reduced the dis-
criminatory power of HRM curve analysis. Despite this limi-
tation, we found that the HRM assay could successfully be
used with heat-denatured isolates for the detection of a range
of key mutations. Furthermore, we found that allele-specific
PCR was a suitable alternative when the HRM assay was
unsuccessful, given that it accurately identified the sequence
types of the mtrR promoter sequence for all isolates. This
shows that the combined used of heat-denatured isolates with
the HRM assay and allele-specific PCR offers a simple, inex-
pensive, and rapid means of detecting a broad range of muta-
tions: each SYBR green reaction costs approximately Aus$1.50
and could be performed in less than 2 h, including the time for
isolate heat treatment. It should be noted that the use of a
DNA extraction method would otherwise have increased the
cost by a minimum of Aus$4.00 per isolate and would have
added approximately 30 min to the sample preparation time.
A notable advantage of detection by the HRM assay ob-
served in this study was that the assay design was relatively
simple, as it has limited primer design requirements. The prim-
ers need to directly flank only the mutations of interest and
need to have a sufficient melting temperature to operate at an
annealing temperature of 60°C under two-step cycling condi-
tions. In fact, we found that strong primer dimers, which were
evident in the G45D HRM assay primers, had no observable
effect on the results of typing by the HRM assay. This was
presumably because the gonococcal DNA load was sufficiently
high for the PCR to favor the specific reaction, limiting the
potential for nonspecific reactions to occur.
A further benefit of the HRM approach was that the se-
quence type results assigned by the HRM assays were largely
unaffected by sequence variation in the regions flanking the
targeted mutations. Mismatches were observed in the HRM
assay primer targets for several isolates, yet this did not result
in the assignment of an incorrect sequence type by the HRM
method. This can be attributed to the fact that upon amplifi-
cation the primer sequences are incorporated into the resulting
PCR product, and therefore, a PCR product can differ in its
sequence composition only if the sequences internal to the
primer targets are different. This is in contrast to probe-based
methods, for which we have previously shown that unexpected
sequence variations can have a significant impact on hybrid-
ization probe-based assays, given that these methods require a
relatively large region of conserved sequence (generally about
50 bases) to accommodate both probes (28). It is highly un-
likely that a hybridization probe-based approach would have
been suitable for many of the targeted mutations in this study,
given the extent of the sequence variation observed. The only
obvious impact that sequence variation in primer targets did
have on the HRM assays was for isolates with the previously
described mosaic penA sequence and those with the porB1a
genes, which failed to be amplified in the penA 345A and porB
HRM assays, respectively. We do not consider this to be a
major limitation, given that these isolates were identified as
variants by the HRM methods, enabling them to be flagged for
DNA sequencing or testing by an alternative detection
method. It should be noted that unexpected mutations in
primer targets do have the potential to affect the accuracy of
allele-specific PCR results. However, such problems were not
observed in this study, presumably because the two mutations
that were observed in the forward primer of the mtrR promoter
allele-specific PCR (Table 3) were not in the extreme 3 end of
the primer.
In conclusion, we found that the heat denaturation DNA
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preparation method combined with SYBR green-based real-
time PCR offers a simple, rapid, and inexpensive means of
detecting N. gonorrhoeae mutations associated with antimicro-
bial resistance. The use of this approach has the potential to
enhance public health-based surveillance for antimicrobial re-
sistance in gonococci and to further our currently incomplete
understanding of gonococcal genetic resistance mechanisms
and the relationships between the different molecular changes
and their effects on phenotypic resistance. Furthermore, we
believe that these methods could be applied in other settings
for the detection of polymorphisms associated with phenotypes
of interest in microbiology and other areas of genetic research.
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